Table 4.
Laboratory measurements for adverse effects monitoring reported in PLD and epirubicin groups.
| Measurements | Total (n = 366) | PLD (n = 183) | Epirubicin (n = 183) | p | |||
|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | n | (%) | ||
| Leukocytes (μL) | 0.606 | ||||||
| ≥3500 | 208 | (59.8) | 105 | (60.3) | 103 | (59.2) | |
| ≥3000–3500 | 56 | (16.1) | 31 | (17.8) | 25 | (14.4) | |
| ≥2000–3000 | 69 | (19.8) | 33 | (19.0) | 36 | (20.7) | |
| ≥1000–2000 | 13 | (3.7) | 4 | (2.3) | 9 | (5.2) | |
| <1000 | 2 | (0.6) | 1 | (0.6) | 1 | (0.6) | |
|
| |||||||
| Absolute neutrophil count (mm3) | 0.510 | ||||||
| ≥2000 | 192 | (55.2) | 95 | (54.6) | 97 | (55.7) | |
| ≥1500–2000 | 82 | (23.6) | 44 | (25.3) | 38 | (21.8) | |
| ≥1000–1500 | 48 | (13.8) | 26 | (14.9) | 22 | (12.6) | |
| ≥500–1000 | 18 | (5.2) | 6 | (3.4) | 12 | (6.9) | |
| <500 | 8 | (2.3) | 3 | (1.7) | 5 | (2.9) | |
|
| |||||||
| Hemoglobin (g/dl) | <0.001 | ||||||
| ≥12 | 62 | (17.8) | 49 | (28.2) | 13 | (7.5) | |
| ≥10–12 | 195 | (56.0) | 91 | (52.3) | 104 | (59.8) | |
| ≥8–10 | 76 | (21.8) | 28 | (16.1) | 48 | (27.6) | |
| ≥6.5–8 | 12 | (3.4) | 5 | (2.9) | 7 | (4.0) | |
| <6.5 | 3 | (0.9) | 1 | (0.6) | 2 | (1.1) | |
|
| |||||||
| Platelets (μL) | 0.644 | ||||||
| ≥150000 | 339 | (97.4) | 169 | (97.1) | 170 | (97.7) | |
| ≥50000-75000 | 6 | (1.7) | 4 | (2.3) | 2 | (1.1) | |
| ≥1000-50000 | 2 | (0.6) | 1 | (0.6) | 1 | (0.6) | |
| <10000 | 1 | (0.3) | 0 | (0.0) | 1 | (0.6) | |
|
| |||||||
| AST (U/L) | 0.745 | ||||||
| ≤87.5 | 324 | (93.1) | 161 | (92.5) | 163 | (93.7) | |
| >87.5–100 | 7 | (2.0) | 3 | (1.7) | 4 | (2.3) | |
| >100–200 | 13 | (3.7) | 7 | (4.0) | 6 | (3.4) | |
| >200–800 | 4 | (1.1) | 3 | (1.7) | 1 | (0.6) | |
|
| |||||||
| ALT (U/L) | 0.490 | ||||||
| ≤87.5 | 294 | (84.5) | 145 | (83.3) | 149 | (85.6) | |
| >87.5–100 | 11 | (3.2) | 8 | (4.6) | 3 | (1.7) | |
| >100–200 | 32 | (9.2) | 16 | (9.2) | 16 | (9.2) | |
| >200–800 | 11 | (3.2) | 5 | (2.9) | 6 | (3.4) | |
p values are estimated using Fisher's exact test.